Premium
Systemische Behandlung von Haut‐Candidosen: Ein randomisierter Vergleich von Terbinafin und Ketoconazol
Author(s) -
Jung E. G.,
Haas P. J.,
Bräutigam M.,
Weidinger G.
Publication year - 1994
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.1994.37.9-10.361
Subject(s) - ketoconazole , terbinafine , medicine , discontinuation , adverse effect , dermatology , mycosis , randomized controlled trial , pharmacology , dermatophyte , itraconazole , antifungal , surgery
Summary Terbinafine is an antimycotic drug which has a much higher in vitro activity against dermatophytes than against yeasts. To investigate the clinical relevance of these in vitro data, 118 patients with cutaneous candidosis were enrolled in a randomized, double‐blind study and allocated to a 4‐week treatment with a daily dose of either 250 mg b.i.d. terbinafine or 200 mg once‐daily ketoconazole. At the final assessment, 3 weeks after cessation of therapy, mycological cure rates (negative culture and negative microscopy) were 82% in the terbinafine group and 73% in the ketoconazole group. Effective treatment with negative mycology and no or minimal signs or symptoms could be achieved in 65% of those who received terbinafine and in 57% of those randomized to ketoconazole. Five per cent and 7% of the patients taking terbinafine and ketoconazole, respectively, complained about adverse events, which were usually mild and did not lead to discontinuation of treatment. In one patient in the ketoconazole group, abnormal liver enzymes were noted at the final laboratory assessment. The results of this study indicate that terbinafine 500 mg daily can be an alternative to ketoconazole when systemic treatment of skin candidosis is required.